Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-1950
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives ; volume:80 ; number:12 ; day:15 ; month:7 ; year:2020 ; pages:1203-1210 ; date:8.2020
Drugs ; 80, Heft 12 (15.7.2020), 1203-1210, 8.2020

Urheber
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s40265-020-01361-5
URN
urn:nbn:de:101:1-2020092800095004549862
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:56 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

Ähnliche Objekte (12)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma

Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis

Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms

Fallstudiensammlung

Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Anti-angiogenesis in hepatocellular carcinoma treatment : current evidence and future perspectives

Anti-angiogenesis in hepatocellular carcinoma treatment : current evidence and future perspectives

Verbundene Objekte